Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma
Status:
Completed
Trial end date:
2019-03-12
Target enrollment:
Participant gender:
Summary
This is an Italian, multicentre, single arm, phase II study, with an intra-patient comparison
end point. This study aims at confirming the activity of the drug trabectedin as
second/further line treatment in retroperitoneal leiomyosarcoma and well
differentiated/dedifferentiated liposarcoma expressed in terms of slowing down tumour growth.
Another objective is to investigate this peculiar benefit of trabectedin in typical
retroperitoneal sarcomas may be exploited to help multidisciplinary clinical decision-making
in the management of retroperitoneal sarcomas